Is there still a room for crizotinib in first-line setting in ALK-positive NSCLC patients?

9 / 39

Toxicity is an issue
Zhu – BMC 2017 * Peters – NEJM 2017 * Camidge – NEJM 2018
23% vs . 32%
P=0.049
Grade ≥ 3 ALEX: 50% vs. 41%
Grade ≥ 3 ALTA: 55% vs. 61%
17 trials (2011 to 2016). N=1826 patients